PET imaging with hypoxia tracers: A must in radiation therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 4, 2008, Pages 838-842

  Lucignani, Giovanni ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 NITROIMIDAZOLE DERIVATIVE; COPPER DIACETYLBIS(N4 METHYLTHIOSEMICARBAZONE) CU 60; COPPER DIACETYLBIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; FLUOROAZOMYCIN ARABINOFURANOSIDE F 18; FLUORODEOXYGLUCOSE F 18; THIOSEMICARBAZONE DERIVATIVE; TIRAPAZAMINE; TRACER; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; HUMAN; HYPOXIA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOCHEMISTRY; SHORT SURVEY; SOLID TUMOR; TREATMENT PLANNING;

ANOXIA; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOTHERAPY;

EID: 40949112266     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0740-2     Document Type: Short Survey

References (16)

1. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26(2):225-39. Jun.
2. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82(10):699-757. Oct.
3. 18F-fluoromisonidazole. Semin Nucl Med. 2007;37(6):451-61. Nov.
4. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007;21(43):4893-902. Nov.
5. 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46(1):106-13. Jan.
6. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol. 2007;17(4):861-72. Apr.
7. Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)f-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):235-42. Jan 1.
8. 18F]-misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol. 2007;83(3):406-10. Jun.
9. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys. 2007;68(2):515-21. Jun 1.
10. 60Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol. 2007;9(5):278-83. Sep-Oct.
11. 18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. 2007;34(10):1566-75. Oct.
12. Grosu AL, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):541-51. Oct 1.
13. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2008;70(1):2-13. Jan 1.
14. 18F]FAZA-first small animal PET results. J Pharm Pharm Sci. 2007;10(2):203-11.
15. Lecchi M, Fossati P, Elisei F, Orecchia R, Lucignani G. Current concepts on imaging in radiotherapy. Eur J Nucl Med Mol Imaging. 2007; DOI 10.1007/s00259-007-0631-y, Oct 31; [Epub ahead of print].
16. Krause BJ, Beck R, Souvatzoglou M, Piert M. PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging. 2006;50(1):28-43. Mar.